CN107667170B - 细胞 - Google Patents

细胞 Download PDF

Info

Publication number
CN107667170B
CN107667170B CN201680030192.8A CN201680030192A CN107667170B CN 107667170 B CN107667170 B CN 107667170B CN 201680030192 A CN201680030192 A CN 201680030192A CN 107667170 B CN107667170 B CN 107667170B
Authority
CN
China
Prior art keywords
leu
gly
glu
ala
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680030192.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107667170A (zh
Inventor
M.普莱
S.科多巴
S.托马斯
K.孔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autolus Ltd filed Critical Autolus Ltd
Publication of CN107667170A publication Critical patent/CN107667170A/zh
Application granted granted Critical
Publication of CN107667170B publication Critical patent/CN107667170B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201680030192.8A 2015-06-01 2016-05-31 细胞 Active CN107667170B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1509413.9A GB201509413D0 (en) 2015-06-01 2015-06-01 Fusion protein
GB1509413.9 2015-06-01
PCT/GB2016/051576 WO2016193696A1 (en) 2015-06-01 2016-05-31 Cell

Publications (2)

Publication Number Publication Date
CN107667170A CN107667170A (zh) 2018-02-06
CN107667170B true CN107667170B (zh) 2021-09-03

Family

ID=53677545

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680030192.8A Active CN107667170B (zh) 2015-06-01 2016-05-31 细胞

Country Status (20)

Country Link
US (2) US11345734B2 (cg-RX-API-DMAC7.html)
EP (2) EP3303568B1 (cg-RX-API-DMAC7.html)
JP (4) JP6833727B2 (cg-RX-API-DMAC7.html)
KR (1) KR102275460B1 (cg-RX-API-DMAC7.html)
CN (1) CN107667170B (cg-RX-API-DMAC7.html)
AU (1) AU2016272457B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017023190A2 (cg-RX-API-DMAC7.html)
CA (1) CA2986956C (cg-RX-API-DMAC7.html)
CL (1) CL2017003057A1 (cg-RX-API-DMAC7.html)
DK (1) DK3303568T3 (cg-RX-API-DMAC7.html)
ES (1) ES2791338T3 (cg-RX-API-DMAC7.html)
GB (1) GB201509413D0 (cg-RX-API-DMAC7.html)
HU (1) HUE050132T2 (cg-RX-API-DMAC7.html)
IL (1) IL255594B (cg-RX-API-DMAC7.html)
MX (1) MX383118B (cg-RX-API-DMAC7.html)
PL (1) PL3303568T3 (cg-RX-API-DMAC7.html)
PT (1) PT3303568T (cg-RX-API-DMAC7.html)
RU (1) RU2729158C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016193696A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201707334B (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
IL297905A (en) 2015-07-28 2023-01-01 Univ Pennsylvania Altered monocytes/macrophages expressing chimeric antigen receptors and their uses
MY196175A (en) 2016-01-11 2023-03-20 Univ Leland Stanford Junior Chimeric Proteins And Methods Of Regulating Gene Expression
AU2017207281B2 (en) * 2016-01-11 2022-03-10 The Board Of Trustees Of The Leland Stanford Junior University Chimeric proteins and methods of immunotherapy
GB201620070D0 (en) * 2016-11-28 2017-01-11 Autolus Ltd Signal transduction modifying protein
GB201621889D0 (en) * 2016-12-21 2017-02-01 Autolus Ltd Cell
EP3585394A4 (en) * 2017-02-23 2021-06-30 Olema Pharmaceuticals, Inc. COMPOSITIONS AND PROCEDURES FOR REGULATING THE ACTIVITY OF THE IMMUNE SYSTEM
EP3589647A1 (en) * 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
GB201707783D0 (en) * 2017-05-15 2017-06-28 Autolus Ltd Cell
EP3634989A1 (en) * 2017-05-15 2020-04-15 Autolus Limited A cell comprising a chimeric antigen receptor (car)
US20200306303A1 (en) * 2017-09-29 2020-10-01 Chiou Hwa YUH Methods and compositions enhancing survival and functionality of anti-tumor and anti-viral t cells
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
WO2019118518A2 (en) * 2017-12-11 2019-06-20 Senti Biosciences, Inc. Inducible cell receptors for cell-based therapeutics
US20210363217A1 (en) * 2018-06-19 2021-11-25 Autolus Limited Cell
CN109294982B (zh) * 2018-09-30 2020-11-06 北京鼎成肽源生物技术有限公司 一种rff2细胞
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
CA3121911A1 (en) * 2018-12-06 2020-06-11 The Board Of Trustees Of The Leland Stanford Junior University Regulatable cell surface receptors and related compositions and methods
GB201820157D0 (en) * 2018-12-11 2019-01-23 Imperial Innovations Ltd Method of treatment
US20220133791A1 (en) 2019-01-23 2022-05-05 Miltenyi Biotec B.V. & Co. KG A Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject
US20220145325A1 (en) 2019-03-08 2022-05-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
CN113710697A (zh) * 2019-03-15 2021-11-26 美国政府(由卫生和人类服务部的部长所代表) 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
EP3966333A1 (en) * 2019-05-07 2022-03-16 ModernaTX, Inc. Polynucleotides for disrupting immune cell activity and methods of use thereof
CN118165120A (zh) * 2019-07-22 2024-06-11 南京助天中科科技发展有限公司 一种嵌合抗原受体及其应用
AU2020341479A1 (en) 2019-09-03 2022-03-31 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
EP4031583A4 (en) * 2019-09-16 2023-11-15 Fred Hutchinson Cancer Center CHIMERIC RECEPTOR PROTEINS AND THEIR USES
JP7773976B2 (ja) * 2019-10-23 2025-11-20 スティヒティング ヘット ネーデルランズ カンケル インスティテュート－アントニ ファン レーウェンフーク ジーケンハウス 免疫細胞制御用キメラポリペプチド
EP4058561A1 (en) * 2019-11-12 2022-09-21 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
MX2022006962A (es) 2019-12-11 2022-09-12 A2 Biotherapeutics Inc Receptor quimerico de antigenos basado en el miembro 1 de la subfamilia b de receptores similares a inmunoglobulina de leucocitos (lilrb1).
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
WO2021156277A1 (en) 2020-02-04 2021-08-12 Miltenyi Biotec B.V. & Co. KG Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
GB202006820D0 (en) 2020-05-07 2020-06-24 Autolus Ltd Cell
GB202007044D0 (en) 2020-05-13 2020-06-24 Autolus Ltd Method
US12286465B2 (en) 2020-05-28 2025-04-29 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
IL298693A (en) 2020-06-04 2023-02-01 Carisma Therapeutics Inc New structures for chimeric antigen receptors
CN116322750A (zh) * 2020-06-25 2023-06-23 卫理公会医院 抗原特异性t细胞受体和嵌合抗原受体以及用于癌症免疫疗法的免疫信号传导调节中的使用方法
CN116724052A (zh) 2020-08-20 2023-09-08 A2生物治疗股份有限公司 用于治疗ceacam阳性癌症的组合物和方法
RS65802B1 (sr) 2020-08-20 2024-08-30 A2 Biotherapeutics Inc Kompozicije i postupci za lečenje egfr pozitivnih kancera
MX2023002041A (es) 2020-08-20 2023-04-27 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para mesotelina.
WO2022093741A1 (en) * 2020-10-26 2022-05-05 Research Development Foundation Mutant proteases and uses thereof
WO2022098905A2 (en) 2020-11-04 2022-05-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
WO2022096664A1 (en) 2020-11-09 2022-05-12 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
CN118703444A (zh) * 2021-01-22 2024-09-27 南京助天中科科技发展有限公司 一种嵌合抗原受体改造的nk细胞及其制备方法与应用
MX2023010916A (es) 2021-03-17 2023-12-14 Myeloid Therapeutics Inc Composiciones de proteinas de fusion quimericas modificadas por ingenieria y metodos de uso de las mismas.
WO2022241029A1 (en) 2021-05-11 2022-11-17 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
JP2023008482A (ja) 2021-07-06 2023-01-19 日本たばこ産業株式会社 たばこ製品の香味料担持構成部材及びこの製造方法
WO2023044304A1 (en) * 2021-09-15 2023-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
WO2023057285A1 (en) 2021-10-06 2023-04-13 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
US20250121003A1 (en) * 2021-11-04 2025-04-17 Dana-Farber Cancer Institute, Inc. Developing inducible cluster chimeric antigen receptor (ccar) constructs
WO2024078995A1 (en) 2022-10-15 2024-04-18 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
GB202312009D0 (en) 2023-08-04 2023-09-20 Autolus Ltd Methods and cell compositions
CN119331105B (zh) * 2024-09-03 2025-10-28 中国人民解放军空军军医大学 靶向多种免疫检查点的通用多肽-protac及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040199A1 (en) * 1995-06-07 1996-12-19 University Of Pennsylvania Methods of inhibiting phagocytosis
WO1997031113A1 (en) * 1996-02-23 1997-08-28 Ariad Pharmaceuticals, Inc. Cell-based assay
CN102070719A (zh) * 2010-11-24 2011-05-25 中国人民解放军第四军医大学 一种白血病干细胞靶向可溶性蛋白TrxHis-hCD47
WO2015075468A1 (en) * 2013-11-21 2015-05-28 Ucl Business Plc Cell

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
GB9908807D0 (en) 1999-04-16 1999-06-09 Celltech Therapeutics Ltd Synthetic signalling molecules
EP1171596A1 (en) 1999-04-16 2002-01-16 Celltech Therapeutics Limited Synthetic transmembrane components
US7060506B2 (en) 2000-01-31 2006-06-13 Cyclacel, Ltd. Compositions and methods for monitoring the modification of modification dependent binding partner polypeptides
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
BR112015023679A2 (pt) * 2013-03-15 2017-10-24 Memorial Sloan Kettering Cancer Center composições e métodos para imunoterapia
MX358472B (es) * 2014-10-09 2018-08-21 Univ Yamaguchi Vector de expresion de receptor de antigeno quimerico (car) y celulas t que expresan car.
GB201620070D0 (en) 2016-11-28 2017-01-11 Autolus Ltd Signal transduction modifying protein
GB201717524D0 (en) * 2017-10-25 2017-12-06 Autolus Ltd Vectors
US20220145325A1 (en) * 2019-03-08 2022-05-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
GB202007044D0 (en) * 2020-05-13 2020-06-24 Autolus Ltd Method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040199A1 (en) * 1995-06-07 1996-12-19 University Of Pennsylvania Methods of inhibiting phagocytosis
WO1997031113A1 (en) * 1996-02-23 1997-08-28 Ariad Pharmaceuticals, Inc. Cell-based assay
CN102070719A (zh) * 2010-11-24 2011-05-25 中国人民解放军第四军医大学 一种白血病干细胞靶向可溶性蛋白TrxHis-hCD47
WO2015075468A1 (en) * 2013-11-21 2015-05-28 Ucl Business Plc Cell

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy;Liza B John等;《OncoImmunology》;20131010;第2卷(第10期);1-3 *
Characterization of the Roles of SH2 Domain-Containing Proteins in T-Lymphocyte Activation by Using Dominant Negative SH2 Domains;JEFFREY P. NORTHROP等;《MOLECULAR AND CELLULAR BIOLOGY》;19960531;第16卷(第5期);2255-2263 *
JEFFREY P. NORTHROP等.Characterization of the Roles of SH2 Domain-Containing Proteins in T-Lymphocyte Activation by Using Dominant Negative SH2 Domains.《MOLECULAR AND CELLULAR BIOLOGY》.1996,第16卷(第5期),2255-2263. *
基因修饰技术开发新型癌症免疫疗法;玉田耕治;《上原纪念生命科学基金会研究报告》;20141231;第28卷;1-4 *

Also Published As

Publication number Publication date
IL255594B (en) 2020-11-30
RU2017145074A (ru) 2019-07-09
US11345734B2 (en) 2022-05-31
DK3303568T3 (da) 2020-07-06
ES2791338T3 (es) 2020-11-03
WO2016193696A1 (en) 2016-12-08
RU2017145074A3 (cg-RX-API-DMAC7.html) 2019-07-17
ZA201707334B (en) 2020-02-26
AU2016272457B2 (en) 2020-12-10
KR20180012762A (ko) 2018-02-06
MX383118B (es) 2025-03-13
HUE050132T2 (hu) 2020-11-30
PL3303568T3 (pl) 2020-11-02
MX2017014630A (es) 2018-06-06
HK1246825A1 (en) 2018-09-14
IL255594A (en) 2018-01-31
CL2017003057A1 (es) 2018-03-16
US20220267404A1 (en) 2022-08-25
US20190023761A1 (en) 2019-01-24
CA2986956A1 (en) 2016-12-08
RU2729158C2 (ru) 2020-08-04
JP2018517410A (ja) 2018-07-05
PT3303568T (pt) 2020-06-08
JP2020115898A (ja) 2020-08-06
CN107667170A (zh) 2018-02-06
EP3303568B1 (en) 2020-05-06
EP3730609A1 (en) 2020-10-28
JP6833727B2 (ja) 2021-02-24
JP2022066380A (ja) 2022-04-28
CA2986956C (en) 2022-03-22
AU2016272457A1 (en) 2017-12-14
GB201509413D0 (en) 2015-07-15
BR112017023190A2 (pt) 2018-07-17
NZ737662A (en) 2021-10-29
EP3303568A1 (en) 2018-04-11
JP2024149818A (ja) 2024-10-18
KR102275460B1 (ko) 2021-07-14

Similar Documents

Publication Publication Date Title
CN107667170B (zh) 细胞
EP3612568B1 (en) Cell
EP3681995B1 (en) Cell
CN113543792A (zh) 包含工程化嵌合抗原受体和car调节剂的组合物和方法
US20190309046A1 (en) Signal transduction modifying protein
US20200199550A1 (en) Cell comprising a chimeric antigen receptor (car)
WO2018211245A1 (en) Cell
CN111479918A (zh) 细胞
CN113366479A (zh) 二聚化剂调节的免疫受体复合物
CN114514247A (zh) Car-cd123载体及其用途
JP6842688B2 (ja) キメラ抗原受容体
HK1246825B (en) Cell
NZ737662B2 (en) Cell
JP7054181B2 (ja) キメラ抗原受容体
BR122025000772A2 (pt) Célula
HK40066141B (zh) 基因工程细胞及其用途
HK40066141A (zh) 基因工程细胞及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: England Atsushi

Applicant after: UCL business Limited

Address before: England Atsushi

Applicant before: UCL Business Co., Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20201127

Address after: England Atsushi

Applicant after: AUTOLUS Ltd.

Address before: England Atsushi

Applicant before: UCL business Ltd.

GR01 Patent grant
GR01 Patent grant